Glucocorticoid inhibitors for treatment of prostate cancer

Patent metadata

Field	Value
Publication number	US-10919929-B2
Application number	US-201415103283-A
Country	US
Kind code	B2
Filing date	Dec 11, 2014
Priority date	Dec 11, 2013
Publication date	Feb 16, 2021
Grant date	Feb 16, 2021

Abstract

The present invention encompasses the recognition that reproducible and detectable changes in the level and or activity of Glucocorticoid Receptor (GR) are associated with incidence and/or risk of Castration Resistant Prostate Cancer (CRPC) and/or doubly resistant prostate cancer, specifically in individuals having prostate cancer and on antiandrogen therapy, and provides for the use of GR inhibitors to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer. In some embodiments, GR inhibitors also have Androgen Receptor (AR) inhibitory activity or are administered in conjunction with AR inhibitors. The present invention also provides technologies for identification and/or characterization of agents to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer; in some embodiments such agents alter level and/or activity of a GR. In some embodiments, provided agents show effects on a GR's activity of regulating transcription of one or more target genes. The present invention also provides systems for using such agents, for example to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer.

First claim

What is claimed is:

1. A method of treating castration resistant prostate cancer or doubly resistant prostate cancer comprising administering to a subject in need thereof a compound having the structure of formula I or III:

or a pharmaceutically acceptable salt thereof, wherein:
each R 1 is —OR, wherein R is optionally substituted phenyl;
R 2 is optionally substituted unsaturated C 2-6 aliphatic;
R s is —H, —OH, —NH 2 , —CH 3 , —Br, —Cl, —F, —I, or —O—C 1-6 alkyl;
m is an integer between 1-8; and
n is 1.

2. The method of claim 1 , wherein R 2 is selected from the group consisting of ethyn-1-yl, 1-propyn-1-yl, 1-butyn-1-yl, ethen-1-yl, 1-propen-1-yl, and 1-buten-1-yl.

3. The method of claim 1 , wherein R 2 is 1-propyn-1-yl.

4. The method of claim 1 , wherein the compound has the structure of formula II-a or formula III-a:

5. The method of claim 1 , wherein the compound has the structure of formula IV:

or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 , wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 , wherein the compound is administered to the subject in need thereof in combination with an androgen receptor inhibitor.

Assignees

• Sloan Kettering Inst Cancer Res

Inventors

• Arora Vivek
• Sawyers Charles L
• Evans Michael J
• Veach Darren R

Classifications

• A61K31/573 Primary

  substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone · CPC title

• G01N33/743

  Steroid hormones · CPC title

• A61K31/416

  condensed with carbocyclic ring systems, e.g. indazole · CPC title

• A61K31/713

  Double-stranded nucleic acids or oligonucleotides · CPC title

• A61K31/7105

  Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links · CPC title